Venaxis expects APPY1 approval following positive trial; shares soar


Venaxis' (APPY) APPY1 Test for identifying patients who are at low risk of appendicitis performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study.

Venaxis believes that the data is enough to receive FDA approval, and the company intends to file a 510(k) application in the next few weeks.

Shares surge 29% premarket. (PR)

From other sites
Comments (3)
  • deercreekvols
    , contributor
    Comments (9721) | Send Message
     
    BINGO!!!!
    13 Mar 2014, 07:48 AM Reply Like
  • mebesalan
    , contributor
    Comments (2) | Send Message
     
    About time
    13 Mar 2014, 12:33 PM Reply Like
  • mebesalan
    , contributor
    Comments (2) | Send Message
     
    About time. How many years have we been waiting!
    13 Mar 2014, 12:33 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs